Literature DB >> 24270445

The search for ESR1 mutations in breast cancer.

Steffi Oesterreich1, Nancy E Davidson.   

Abstract

Two new studies report the identification of activating ESR1 gene mutations in aromatase inhibitor-resistant metastatic breast cancers. This insight into therapeutic resistance suggests new approaches that may be useful in the management of endocrine-resistant breast cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24270445      PMCID： PMC4934882          DOI： 10.1038/ng.2831

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  13 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.

Authors:  G Lazennec; T R Ediger; L N Petz; A M Nardulli; B S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  1997-08

Review 3.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 4.  Estrogen receptor phosphorylation.

Authors:  Deborah A Lannigan
Journal:  Steroids       Date:  2003-01       Impact factor: 2.668

5.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.

Authors:  K E Weis; K Ekena; J A Thomas; G Lazennec; B S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  1996-11

6.  An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.

Authors:  Q X Zhang; A Borg; D M Wolf; S Oesterreich; S A Fuqua
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

7.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

Authors:  Shunqiang Li; Dong Shen; Jieya Shao; Robert Crowder; Wenbin Liu; Aleix Prat; Xiaping He; Shuying Liu; Jeremy Hoog; Charles Lu; Li Ding; Obi L Griffith; Christopher Miller; Dave Larson; Robert S Fulton; Michelle Harrison; Tom Mooney; Joshua F McMichael; Jingqin Luo; Yu Tao; Rodrigo Goncalves; Christopher Schlosberg; Jeffrey F Hiken; Laila Saied; Cesar Sanchez; Therese Giuntoli; Caroline Bumb; Crystal Cooper; Robert T Kitchens; Austin Lin; Chanpheng Phommaly; Sherri R Davies; Jin Zhang; Megha Shyam Kavuri; Donna McEachern; Yi Yu Dong; Cynthia Ma; Timothy Pluard; Michael Naughton; Ron Bose; Rama Suresh; Reida McDowell; Loren Michel; Rebecca Aft; William Gillanders; Katherine DeSchryver; Richard K Wilson; Shaomeng Wang; Gordon B Mills; Ana Gonzalez-Angulo; John R Edwards; Christopher Maher; Charles M Perou; Elaine R Mardis; Matthew J Ellis
Journal:  Cell Rep       Date:  2013-09-19       Impact factor: 9.423

8.  Whole-genome analysis informs breast cancer response to aromatase inhibition.

Authors:  Matthew J Ellis; Li Ding; Dong Shen; Jingqin Luo; Vera J Suman; John W Wallis; Brian A Van Tine; Jeremy Hoog; Reece J Goiffon; Theodore C Goldstein; Sam Ng; Li Lin; Robert Crowder; Jacqueline Snider; Karla Ballman; Jason Weber; Ken Chen; Daniel C Koboldt; Cyriac Kandoth; William S Schierding; Joshua F McMichael; Christopher A Miller; Charles Lu; Christopher C Harris; Michael D McLellan; Michael C Wendl; Katherine DeSchryver; D Craig Allred; Laura Esserman; Gary Unzeitig; Julie Margenthaler; G V Babiera; P Kelly Marcom; J M Guenther; Marilyn Leitch; Kelly Hunt; John Olson; Yu Tao; Christopher A Maher; Lucinda L Fulton; Robert S Fulton; Michelle Harrison; Ben Oberkfell; Feiyu Du; Ryan Demeter; Tammi L Vickery; Adnan Elhammali; Helen Piwnica-Worms; Sandra McDonald; Mark Watson; David J Dooling; David Ota; Li-Wei Chang; Ron Bose; Timothy J Ley; David Piwnica-Worms; Joshua M Stuart; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2012-06-10       Impact factor: 49.962

9.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

10.  Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region.

Authors:  S Ali; D Metzger; J M Bornert; P Chambon
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598
View more
  30 in total

Review 1.  Tumorigenesis: it takes a village.

Authors:  Doris P Tabassum; Kornelia Polyak
Journal:  Nat Rev Cancer       Date:  2015-07-02       Impact factor: 60.716

2.  New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies.

Authors:  Rachel C Jankowitz; Steffi Oesterreich; Adrian V Lee; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2016-12-15       Impact factor: 12.531

Review 3.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

4.  Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.

Authors:  Thushangi N Pathiraja; Shweta R Nayak; Yuanxin Xi; Shiming Jiang; Jason P Garee; Dean P Edwards; Adrian V Lee; Jian Chen; Martin J Shea; Richard J Santen; Frank Gannon; Sara Kangaspeska; Jaroslav Jelinek; Jean-Pierre J Issa; Jennifer K Richer; Anthony Elias; Marie McIlroy; Leonie S Young; Nancy E Davidson; Rachel Schiff; Wei Li; Steffi Oesterreich
Journal:  Sci Transl Med       Date:  2014-03-26       Impact factor: 17.956

Review 5.  The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.

Authors:  Sasha M Pejerrey; Derek Dustin; Jin-Ah Kim; Guowei Gu; Yassine Rechoum; Suzanne A W Fuqua
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

6.  A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.

Authors:  Shweta R Nayak; Emily Harrington; David Boone; Ryan Hartmaier; Jian Chen; Thushangi N Pathiraja; Kristine L Cooper; Jeffrey L Fine; Joseph Sanfilippo; Nancy E Davidson; Adrian V Lee; David Dabbs; Steffi Oesterreich
Journal:  Horm Cancer       Date:  2015-06-26       Impact factor: 3.869

7.  HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.

Authors:  Luke Whitesell; Sandro Santagata; Marc L Mendillo; Nancy U Lin; David A Proia; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

8.  Can circulating tumor cells predict resistance in metastatic breast cancer?

Authors:  Aju Mathew; Adam M Brufsky; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2015-02-02       Impact factor: 12.531

9.  Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Authors:  Maura N Dickler; William T Barry; Constance T Cirrincione; Matthew J Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S Rugo; Diana E Lake; Olwen Hahn; Bryan P Schneider; Debasish Tripathy; Lisa A Carey; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

10.  ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

Authors:  David Chu; Costanza Paoletti; Christina Gersch; Dustin A VanDenBerg; Daniel J Zabransky; Rory L Cochran; Hong Yuen Wong; Patricia Valda Toro; Justin Cidado; Sarah Croessmann; Bracha Erlanger; Karen Cravero; Kelly Kyker-Snowman; Berry Button; Heather A Parsons; W Brian Dalton; Riaz Gillani; Arielle Medford; Kimberly Aung; Nahomi Tokudome; Arul M Chinnaiyan; Anne Schott; Dan Robinson; Karen S Jacks; Josh Lauring; Paula J Hurley; Daniel F Hayes; James M Rae; Ben Ho Park
Journal:  Clin Cancer Res       Date:  2015-08-10       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.